Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

    A. Batalov
    A. Batalov
    R. Stoilov
    R. Stoilov
    T. Wagner
    T. Wagner
    D. Saurigny
    D. Saurigny
    B. Souberbielle
    B. Souberbielle
    E. Esfandiari
    E. Esfandiari

    Arthritis Research & Therapy, pp. 532017.

    Cited by: 4|Bibtex|Views0|
    Keywords:
    GM-CSF Namilumab Phase 1b Rheumatoid arthritis

    Abstract:

    BackgroundNamilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity to the GM-CSF ligand. This was a phase 1b, randomized, double-blind study (PRIORA) to assess namilumab in active, mild-to-moderate rheumatoid arthritis (RA). The primary outcome was the safety and tolerability of repeated subcutaneous in...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments